Different progestins in the treatment of endometriosis – are there relevant differences?
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
Different oral progestins, despite varying potencies and effects on endocrine and metabolic pathways, are similarly effective for endometriosis symptoms when adequately dosed.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Oral progestins without an estrogen component have been described to be effective in the treatment of endometriosis. Several different substances have been tested, which are on the one hand derivatives of the natural progesterone or of the C-17-OH-progesteron, or on the other hand derivatives of C-19-nortestosteron. Their common characteristic is the secretory transformation of estrogen primed uterine endometrium for which different dosages are necessary because of their different biological activities. They are different with regard to their profile and potency of action on hypothalamicpituitary axis, metabolic processes, breast tissue and genital organs. They are effectively similar with regard to endometriosis related complaints if sufficient doses are administered. No effects are noted on reduced fertility in endometriotic patients and the data are inconsistent concerning direct effects on the endometriotic cells.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (15)
- A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis via openalex
- Aromatase and other steroidogenic genes in endometriosis: translational aspects via openalex
- Deficient 17 -Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17 -Estradiol via openalex
- Deficient 17β-Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17β-Estradiol<sup>1</sup> via openalex
- Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex
- Effects of Progestin-Induced Pseudopregnancy on Endometriosis: Clinical and Microscopic Studies via openalex
- Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis via openalex
- Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells via openalex
- Progestins for symptomatic endometriosis: a critical analysis of the evidence via openalex
- Steroidal regulation of endometriosis tissue: lack of induction of 17β-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol via openalex
- The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex
- The place of dydrogesterone in the treatment of endometriosis and adenomyosis via openalex
- W2101417341 via openalex
- W2052392275 via openalex
- W2469310051 via openalex
Cited by (3)
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:16:54.825375+00:00
License: CC0
· commercial use OK